SOLICITATION NOTICE
R -- Professional Service to support NIMH's NeuroAIDS Therapeutic Initiatives
- Notice Date
- 5/26/2010
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI-1589728
- Archive Date
- 7/2/2010
- Point of Contact
- Liem T Nguyen, Phone: 3014358780
- E-Mail Address
-
ln18x@nih.gov
(ln18x@nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- The National Institute on Drug Abuse (NIDA), Office of Acquisitions Station Support Simplified Acquisitions Branch on behalf of the National Institute of Mental Health (NIMH) intends to negotiate, on a non-competitive basis, with Dr. Deborah Ann (Bravo) Colosi, 6218 Wagner Lane, Bethesda, MD 20816, for professional service to support the NIMH's NeuroAIDS Therapeutic Initiative. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority of FAR 13.106-1(b)(1) and FAR 13.501 (a)(1) to use Simplified Acquisition Procedure for commercial items. The North American Industry Classification System Code is 541690 and the business size standard is $7.0 million. Therapeutic approaches have realized much success in managing HIV/AIDS, however strategies to prevent or treat the neurological complications that frequently accompany HIV disease have been less successful. This is due to limited availability of drugs across the blood brain barrier, the high degree of toxicity that accompanies long term use of current antiretroviral drugs, and the co-morbid mental health conditions that frequently accompany HIV/CNS disease, such as depression, anxieties, mood disorders, as well as others. While the extreme manifestations of AIDS dementia complex have decreased in frequency, less severe but nevertheless debilitating neurological complications persist. This is particularly important as individuals with HIV are living longer with compromised ability to function, also exacerbated by the normal aging processes in an increasing proportion of this population. The National Institute of Mental Health (NIMH) Center for Mental Health Research on AIDS (CMHRA) proposes to expand the therapeutics program by developing several initiatives to identify new therapeutic targets emerging from basic HIV neuropathogenesis research, and foster the pre-clinical and clinical testing of these drugs through mechanisms supportive of these approaches. The vendor shall perform the following tasks: 1. Develop several funding announcements which are part of an integrated strategy to expand on the development and testing of new therapeutic agents for the prevention and treatment of the neurological consequences of HIV/CNS disease. 2. Conduct the background research for these announcements, and consult with the Contracting Officer's Technical Representative (COTR) weekly to discuss current scientific approaches, ongoing clinical trials, and optimal strategies that should be incorporated into these announcements. 3. Assist Program in the development and management of the CHARTER contract extension. 4. Following the post review, assist Program in implementation and management of the next phase of this contract. 5. Provide technical and scientific assistance to the COTR in managing income of applications in response to these FOAs, assist in programmatic review of the science proposed in these applications, and assist program in management of the funding process for those selected. Dr. Colosi has more than 5 years experience working in at Bayer HealthCare Pharmaceuticals. During that time, she participated in all aspects of the process of moving drugs from bench to bedside. This includes basic science research, planning and reviewing clinical trials, analyzing and summarizing results, and licensing issues. She has experience developing and reviewing bioassays for drug efficacy, as well as biotechnology, including proteomic technologies. In addition, Dr. Colosi has a strong background in basic science, including biochemistry and virology, as seen by her doctoral and post-doctoral research experience, which is essential to understand the complexities of targeting therapeutic interventions to HIV-mediated cell dysfunction. The CMHRA currently has a need for an expert with this expertise in the drug development process and yet the need for a strong programmatic approach to therapeutics in NeuroAIDS. Dr. Colosi has been researching the current state of therapeutic approaches to managing HIV/CNS disease over the past 6 months and has written an extensive review of this area. In addition, she has convened a meeting with some of the leaders in the field to review our current efforts and develop a set of recommendations for next steps. Given the extent of her knowledge, Dr. Colosi is considered uniquely positioned to move the NIMH's proposed approaches to the next phase. Not only does this initiative require knowledge of the field, but it also requires an understanding of existing programs at NIMH in order to leverage resources and maximize use of limited funds. Dr. Colosi has had past experiences with the workshops that she convened. Dr. Colosi's previous work for the NIMH has been outstanding and her continuation is critical to the development of this important program to improve the lives of individuals living with HIV. It is determined that Dr. Colosi is the only source qualified to perform the required services. No other sources will satisfy the agency's requirement. The period of performance is to be twelve (12) months from date of award. Place of performance is to be at the NIH main campus located in Bethesda, Maryland 20892. This acquisition is a fee-for-service type. This is not a solicitation for competitive quotations. However, interested party may submit a statement of capabilities on or before 2:00 PM E.T., June 4, 2010 to Liem T Nguyen, ln18x@nih.gov. All information furnished must be in writing and must contain sufficient detail to allow the NIDA/NIMH to determine if it can meet the above unique specifications described herein. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NIDA vendor must be registered in the Online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov. In addition, vendor must be registered in the Central Contractor Registration (CCR) at www.ccr.gov. Please reference announcement number NOI-1589728 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI-1589728/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02160890-W 20100528/100526235134-801706b4dda3c488321b8f6e4f7918cb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |